Published in J Affect Disord on April 06, 2012
Epigenetic Modulation of Mood Disorders. J Genet Syndr Gene Ther (2013) 0.98
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry (2007) 2.45
Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry (2006) 2.29
The poor prognosis of childhood-onset bipolar disorder. J Pediatr (2007) 2.26
Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biol Psychiatry (2002) 2.26
Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry (2011) 2.20
Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry (2008) 2.17
Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized, placebo-controlled trial followed by single-blind extension. J Clin Psychiatry (2014) 2.13
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry (2005) 1.98
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry (2007) 1.95
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Early physical and sexual abuse associated with an adverse course of bipolar illness. Biol Psychiatry (2002) 1.93
World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res (2008) 1.84
Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry (2002) 1.71
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry (2012) 1.69
Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry (2003) 1.68
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry (2009) 1.55
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry (2012) 1.55
High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry (2002) 1.48
Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord (2007) 1.46
Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: a double-blind controlled pilot study. Menopause (2006) 1.45
Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry (2005) 1.44
Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J Clin Psychiatry (2003) 1.44
Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42
New designs for studies of the prophylaxis of bipolar disorder. J Clin Psychopharmacol (2002) 1.39
Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action. Biol Psychiatry (2004) 1.39
Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A (2009) 1.38
Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev (2007) 1.36
Juvenile maladaptive aggression: a review of prevention, treatment, and service configuration and a proposed research agenda. J Clin Psychiatry (2006) 1.31
A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol (2009) 1.28
Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology (2010) 1.25
Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry (2006) 1.24
Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2009) 1.23
The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci (2008) 1.19
Principal components of the Beck Depression Inventory and regional cerebral metabolism in unipolar and bipolar depression. Biol Psychiatry (2002) 1.18
Multifocal slow potential generation revealed by high-resolution EEG and current density reconstruction. Int J Psychophysiol (2002) 1.17
Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study. Biol Psychiatry (2005) 1.17
Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry (2005) 1.17
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry (2005) 1.16
The generators of slow potentials obtained during verbal, pictorial and spatial tasks. Int J Psychophysiol (2003) 1.16
Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: a sex-specific phenomenon. Arch Gen Psychiatry (2005) 1.16
Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network. Am J Psychiatry (2004) 1.13
Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry (2006) 1.13
A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci U S A (2010) 1.11
Taenia solium DNA is present in the cerebrospinal fluid of neurocysticercosis patients and can be used for diagnosis. Eur Arch Psychiatry Clin Neurosci (2006) 1.11
Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm (Vienna) (2008) 1.10
Does lithium prevent Alzheimer's disease? Drugs Aging (2012) 1.10
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry (2006) 1.10
Is there progression from irritability/dyscontrol to major depressive and manic symptoms? A retrospective community survey of parents of bipolar children. J Affect Disord (2003) 1.09
Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biol Psychiatry (2005) 1.09
Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry (2011) 1.09
Reduced cortical folding in schizophrenia: an MRI morphometric study. Am J Psychiatry (2003) 1.08
Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res (2008) 1.08
Gender differences in prevalence, risk, and clinical correlates of alcoholism comorbidity in bipolar disorder. Am J Psychiatry (2003) 1.07
Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology (2008) 1.07
Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol (2008) 1.05
Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep (2011) 1.05
Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illness. Compr Psychiatry (2003) 1.05
Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry (2009) 1.04
Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.03
Age, sex and laterality effects on cerebral glucose metabolism in healthy adults. Psychiatry Res (2002) 1.03
Left prefrontal-repetitive transcranial magnetic stimulation (rTMS) and regional cerebral glucose metabolism in normal volunteers. Psychiatry Res (2002) 1.00
Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry (2004) 1.00
Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry (2014) 1.00
Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry (2006) 0.99
Hypomania: a transcultural perspective. World Psychiatry (2010) 0.99
Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr Res (2003) 0.99
Reduced serum nerve growth factor in patients with late-life depression. Am J Geriatr Psychiatry (2013) 0.98
Proteome analysis of schizophrenia brain tissue. World J Biol Psychiatry (2010) 0.97
An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol (2011) 0.97
Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. J Affect Disord (2010) 0.97
Mild cognitive impairment: cognitive screening or neuropsychological assessment? Rev Bras Psiquiatr (2008) 0.97
Insights into Alzheimer disease pathogenesis from studies in transgenic animal models. Clinics (Sao Paulo) (2011) 0.96
Daily left prefrontal repetitive transcranial magnetic stimulation for acute treatment of medication-resistant depression. Am J Psychiatry (2011) 0.96
Maternal deprivation increases cell death in the infant rat brain. Brain Res Dev Brain Res (2002) 0.96
Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat (2013) 0.95
Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. Depress Anxiety (2013) 0.95
Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder? Neurobiol Dis (2010) 0.94
Intensity-dependent regional cerebral blood flow during 1-Hz repetitive transcranial magnetic stimulation (rTMS) in healthy volunteers studied with H215O positron emission tomography: II. Effects of prefrontal cortex rTMS. Biol Psychiatry (2003) 0.94
D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology (Berl) (2014) 0.93
Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease. Neuromolecular Med (2012) 0.93
Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med (2010) 0.93
Intensity-dependent regional cerebral blood flow during 1-Hz repetitive transcranial magnetic stimulation (rTMS) in healthy volunteers studied with H215O positron emission tomography: I. Effects of primary motor cortex rTMS. Biol Psychiatry (2003) 0.93
Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett (2011) 0.93
Reduced serum levels of adiponectin in elderly patients with major depression. J Psychiatr Res (2012) 0.92
Decreased expression of mineralocorticoid receptor mRNA in the prefrontal cortex in schizophrenia and bipolar disorder. Int J Neuropsychopharmacol (2004) 0.91
Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. J Clin Psychiatry (2007) 0.90
Pharmacogenomics of antidepressant induced mania: a review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. J Affect Disord (2011) 0.90
A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord (2007) 0.89
Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): a pilot study. Brain Res Bull (2011) 0.89
The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials. CNS Spectr (2006) 0.89
Alcoholism and anxiety in bipolar illness: differential lifetime anxiety comorbidity in bipolar I women with and without alcoholism. J Affect Disord (2007) 0.89
Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease. J Psychiatr Res (2010) 0.89